The Phase 3b COSMOS study (NCT03796858) investigated efficacy and safety of guselkumab in patients with psoriatic arthritis who had inadequate response to TNF inhibitors. touchIMMUNOLOGY caught up with Prof. Laure Gossec (Sorbonne Université, Paris, France) to discuss her analysis assessing efficacy of guselkumab by multi-domain composite indices.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population.’ (Abstract number: 2110) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you give us a brief overview of the current therapeutic landscape for psoriatic arthritis (PsA)? (0:18)
- What is the treatment target and how is this assessed? (1:02)
- What did the COSMOS study teach us about the efficacy and safety of guselkumab in psoriatic arthritis? (2:28)
- What was the purpose of the analysis you are presenting and what disease indices were assessed? (3:37)
- What were the findings of the analysis? (5:08)
- What does this study tell us about composite scores in PsA? (7:08)
Disclosures: Laure Gossec discloses consulting for Janssen in relation to this video interview.Â
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
